These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 27942977

  • 1. Maintenance of efficacy and safety with subcutaneous golimumab in rheumatoid arthritis patients with low disease activity who previously received TNF inhibitors.
    Wakabayashi H, Inada H, Nishioka Y, Hasegawa M, Sudo A, Nishioka K.
    Clin Rheumatol; 2017 Apr; 36(4):941-946. PubMed ID: 27942977
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events.
    Wakabayashi H, Inada H, Nishioka Y, Hasegawa M, Nishioka K, Sudo A.
    Drugs R D; 2017 Mar; 17(1):233-239. PubMed ID: 28025727
    [Abstract] [Full Text] [Related]

  • 3. Long-Term Maintenance of Golimumab Effectiveness for Injection Spacing in Rheumatoid Arthritis Patients with Low Disease Activity Who Previously Received Other TNF Inhibitors: Minimum 2-year Data From an Observational Study.
    Wakabayashi H, Nagao N, Inada H, Nishioka Y, Hasegawa M, Nishioka K, Sudo A.
    Drugs R D; 2021 Sep; 21(3):351-357. PubMed ID: 34173221
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU, GO-AFTER study investigators.
    Lancet; 2009 Jul 18; 374(9685):210-21. PubMed ID: 19560810
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical response to golimumab in rheumatoid arthritis patients who were receiving etanercept or adalimumab: results of a multicenter active treatment study.
    Huffstutter JE, Kafka S, Brent LH, Matucci-Cerinic M, Tang KL, Chevrier M, Sprabery T, DeHoratius RJ.
    Curr Med Res Opin; 2017 Apr 18; 33(4):657-666. PubMed ID: 28035867
    [Abstract] [Full Text] [Related]

  • 8. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study.
    Zhuang Y, Xu Z, Frederick B, de Vries DE, Ford JA, Keen M, Doyle MK, Petty KJ, Davis HM, Zhou H.
    Clin Ther; 2012 Jan 18; 34(1):77-90. PubMed ID: 22169051
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study.
    Combe B, Dasgupta B, Louw I, Pal S, Wollenhaupt J, Zerbini CA, Beaulieu AD, Schulze-Koops H, Durez P, Yao R, Vastesaeger N, Weng HH, GO-MORE Investigators.
    Ann Rheum Dis; 2014 Aug 18; 73(8):1477-86. PubMed ID: 23740226
    [Abstract] [Full Text] [Related]

  • 10. Comparison of golimumab 100-mg monotherapy to golimumab 50 mg plus methotrexate in patients with rheumatoid arthritis: Results from a multicenter, cohort study.
    Yonemoto Y, Okamura K, Takeuchi K, Ayabe K, Kaneko T, Matsushita M, Tamura Y, Iso T, Okura C, Otsuka K, Inoue H, Takagishi K.
    Mod Rheumatol; 2016 Aug 18; 26(1):24-8. PubMed ID: 26140464
    [Abstract] [Full Text] [Related]

  • 11. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
    Boyce EG, Halilovic J, Stan-Ugbene O.
    Clin Ther; 2010 Sep 18; 32(10):1681-703. PubMed ID: 21194591
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
    Li Z, Zhang F, Kay J, Fei K, Han C, Zhuang Y, Wu Z, Hsia EC.
    Int J Rheum Dis; 2016 Nov 18; 19(11):1143-1156. PubMed ID: 26259617
    [Abstract] [Full Text] [Related]

  • 14. Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure.
    Wakabayashi H, Hasegawa M, Nishioka Y, Minami Y, Nishioka K, Sudo A.
    Clin Rheumatol; 2013 Feb 18; 32(2):253-9. PubMed ID: 23179002
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis.
    Keystone EC, Pope JE, Thorne JC, Poulin-Costello M, Phan-Chronis K, Vieira A, Haraoui B, CAMEO Investigators.
    Rheumatology (Oxford); 2016 Feb 18; 55(2):327-34. PubMed ID: 26361879
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab.
    Taylor PC, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, Mack M, Kremer J.
    J Rheumatol; 2011 Dec 18; 38(12):2572-80. PubMed ID: 22089463
    [Abstract] [Full Text] [Related]

  • 20. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis.
    Cohen G, Courvoisier N, Cohen JD, Zaltni S, Sany J, Combe B.
    Clin Exp Rheumatol; 2005 Dec 18; 23(6):795-800. PubMed ID: 16396697
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.